At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of FDA Authorized Smokeless Tobacco Claims Among US Adults Who Smoke Cigarettes
In Brief
A clinical study evaluating Modified Risk Claim Type - None, Product Brand - General Snus, and 3 other interventions for Tobacco Product Beliefs and Use. Completed, enrolled 1,257 participants across 1 site.
Detailed Summary
This study will be an online survey experiment conducted with adults who smoke cigarettes (ages 21+) to examine their reactions to modified risk advertising claims authorized by the Food \& Drug Administration (FDA) for two smokeless tobacco brands (General Snus and Copenhagen), which describe the lower risks of these products compared to cigarette smoking. The study will compare effects of ads with different two different claim types (i.e. claims about reduced lung cancer risk and claims about reduced risks for multiple disease) versus ads with no reduced-risk claims, and examine effects on message and product perceptions, and interest in using the smokeless tobacco products. This study will also examine how smokers' reactions/interest may vary based on the product brand, and asses prior awareness/exposure to the authorized claims.
Study Details
Timeline
Interventions
Participants will view smokeless tobacco ads with no modified risk claim (control)
Participants will views ads for the smokeless tobacco brand General Snus
Participants will views ads for the smokeless tobacco brand Copenhagen
Participants will view smokeless tobacco ads with a claim about lower risks for multiple diseases
Participants will either view smokeless tobacco ads with a modified risk claim about lower risks for lung cancer only